Checkpoint Therapeutics Reports Full-Year 2019 Financial Results and Recent Corporate Highlights
March 11, 2020 16:15 ET
|
Checkpoint Therapeutics, Inc
NEW YORK, March 11, 2020 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage, immuno-oncology biopharmaceutical company focused on the acquisition,...
Checkpoint Therapeutics Announces Confirmation of Registration Path for Cosibelimab in Metastatic Cutaneous Squamous Cell Carcinoma
January 13, 2020 08:15 ET
|
Checkpoint Therapeutics, Inc
FDA feedback supports plan to submit Biologics License Application (BLA) based on data from ongoing Phase 1 trialOne-third enrollment complete in cohort of patients with metastatic cutaneous squamous...
Checkpoint Therapeutics Announces Pricing of Public Offering of Common Stock
November 20, 2019 09:20 ET
|
Checkpoint Therapeutics, Inc
NEW YORK, Nov. 20, 2019 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced the pricing of...
Checkpoint Therapeutics Announces Proposed Public Offering of Common Stock
November 19, 2019 16:01 ET
|
Checkpoint Therapeutics, Inc
NEW YORK, Nov. 19, 2019 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that it is...
Checkpoint Therapeutics Announces Presentation of Anti-PD-L1 Cosibelimab Data at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 08, 2019 07:30 ET
|
Checkpoint Therapeutics, Inc
NEW YORK, Nov. 08, 2019 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (Checkpoint) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that new...
Checkpoint Therapeutics Reports Third Quarter 2019 Financial Results and Recent Corporate Highlights
November 07, 2019 16:30 ET
|
Checkpoint Therapeutics, Inc
NEW YORK, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage, immunotherapy and targeted oncology company, today announced financial...
Checkpoint Therapeutics Announces Presentation of Positive Interim Clinical Results for Anti-PD-L1 Cosibelimab at the European Society for Medical Oncology (ESMO) Congress 2019
September 30, 2019 07:30 ET
|
Checkpoint Therapeutics, Inc
50% objective response rate observed in cutaneous squamous cell carcinoma (CSCC)40% objective response rate observed in non-small cell lung cancerWell-tolerated safety profile across all...
Checkpoint Therapeutics to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference
September 26, 2019 08:30 ET
|
Checkpoint Therapeutics, Inc
NEW YORK, Sept. 26, 2019 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immuno-oncology biopharmaceutical company focused on the acquisition,...
Checkpoint Therapeutics Announces Data Presentation at the European Society for Medical Oncology (ESMO) Congress 2019
September 16, 2019 07:30 ET
|
Checkpoint Therapeutics, Inc
NEW YORK, Sept. 16, 2019 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immuno-oncology biopharmaceutical company focused on the acquisition,...
Checkpoint Therapeutics to Present at September 2019 Investor Conferences
September 04, 2019 08:30 ET
|
Checkpoint Therapeutics, Inc
NEW YORK, Sept. 04, 2019 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage, immuno-oncology biopharmaceutical company focused on the acquisition,...